Stock FYB FORMYCON AG
Add to a list
To use this feature you must be a member
Log inSign up

All News Formycon AG

Equities

FYB

DE000A1EWVY8

Market Closed - Xetra
Other stock markets
 16:36:15 26/04/2024 BST 		5-day change 1st Jan Change
39.95 EUR +0.63% Intraday chart for Formycon AG +3.36% -29.17%
04-25 Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-18 Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQ
DD: Formycon AG: Dr. Stefan Glombitza, buy
EQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case
AQ
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQ
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
EQ
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
EQ
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
EQ
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada
AQ
Updates On Aflibercept BPCIA Litigation
AQ
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar
MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
DJ
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
EQ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia
MT
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
EQ
Updates On Aflibercept BPCIA Litigation
AQ
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million
MT
Gedeon Richter becomes strategic investor of Formycon via equity investment
EQ
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
EQ
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FYB Stock
  4. News Formycon AG